糖尿病患者大疱性类天疱疮与二肽基肽酶-4抑制剂的关联:估计新型药物的风险并描述患者特征
一项回顾性病例对照研究纳入82例糖尿病合并免疫病理确诊的大疱性类天疱疮(BP)患者和328例年龄、性别、族裔匹配的糖尿病对照,发现DPP-4抑制剂暴露与BP风险升高相关(调整OR 3.2,95%CI 1.9-5.4),维格列汀和利格列汀的调整OR分别为10.7和6.7;DPP-4抑制剂相关BP患者黏膜受累更多、外周血嗜酸性粒细胞计数更低,停药后临床结局改善。
要点
- DPP-4抑制剂暴露与糖尿病患者的BP风险升高相关,调整OR为3.2(95%CI 1.9-5.4)。
- 维格列汀调整OR为10.7(95%CI 5.1-22.4),利格列汀调整OR为6.7(95%CI 2.2-19.7)。
- DPP-4抑制剂相关BP患者黏膜受累比例更高(22.2% vs 6.5%,P=0.04),外周血嗜酸性粒细胞计数更低(399.8 vs 1117.6 cells/μL,P=0.01)。
核心结论
- 维格列汀及程度较轻的利格列汀与BP风险升高相关,可能部分解释以色列BP发病率上升。
- 当诊断BP时,应考虑停用糖尿病患者的DPP-4抑制剂治疗。
研究设计与样本
- 回顾性病例对照研究,纳入以色列北部一家自身免疫性大疱病三级转诊中心2011年1月1日至2017年12月31日诊断的82例糖尿病合并免疫病理确诊BP患者,以及328例年龄、性别、族裔匹配的无BP糖尿病对照。
主要发现
- DPP-4抑制剂暴露与BP风险升高相关,调整OR为3.2(95%CI 1.9-5.4)。
- 维格列汀和利格列汀的调整OR分别为10.7(95%CI 5.1-22.4)和6.7(95%CI 2.2-19.7)。
- DPP-4抑制剂使用与BP的关联独立于二甲双胍使用,男性(OR 4.46,95%CI 2.11-9.40)强于女性(OR 1.88,95%CI 0.92-3.86),在70岁以下患者中最强(OR 5.59,95%CI 1.73-18.01)。
- DPP-4抑制剂相关BP患者黏膜受累比例高于未暴露者(22.2% vs 6.5%,P=0.04),外周血嗜酸性粒细胞计数均值(SD)低于未暴露者(399.8 [508.0] vs 1117.6 [1847.6] cells/μL,P=0.01)。
- 停用DPP-4抑制剂后临床结局改善。
临床怎么用
- 作者认为,当诊断BP时,应考虑停用糖尿病患者的DPP-4抑制剂治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The association of bullous pemphigoid (BP) with the use of dipeptidyl-peptidase 4 (DPP-4) inhibitors among patients with diabetes has recently emerged. The risk of developing BP during treatment with new DPP-4 inhibitor agents like linagliptin is yet to be established. The clinical features and the prognostic outcomes of patients with DPP-4 inhibitor-associated BP are yet to be established. OBJECTIVES: Primarily to estimate the association between DPP-4 inhibitor exposure and the development of BP, and secondarily to characterize the clinical features and history of patients with DPP-4 inhibitor-associated BP. DESIGN, SETTING, AND PARTICIPANTS: A retrospective case-control study of the intake of different DPP-4 inhibitor agents and metformin and occurrence of BP among patients with diabetes in a tertiary care referral center for autoimmune bullous diseases in northern Israel. Included were 82 consecutive patients with diabetes and immunopathologically validated BP diagnosed between January 1, 2011, and December 31, 2017, and 328 age-, sex-, and ethnicity-matched control participants with diabetes but without BP. MAIN OUTCOMES AND MEASURES: Patients with diabetes and BP and exposure to DPP-4 inhibitors were followed up for a median of 2.0 years and compared with other patients with diabetes and BP who were not exposed to DPP-4 inhibitors regarding clinical and immunological features, laboratory analyses, treatments, and clinical outcomes. RESULTS: Eighty-two patients with BP and 328 age- and sex-matched control participants were enrolled; mean (SD) age, 79.1 (9.1) years; and 44 patients were female (53.7%). Overall, DPP-4 inhibitor intake was associated with a 3-fold increased risk for BP (adjusted odds ratio [OR], 3.2; 95% CI, 1.9-5.4). The adjusted ORs for vildagliptin and linagliptin were 10.7 (95% CI, 5.1-22.4) and 6.7 (95% CI, 2.2-19.7), respectively. The association of DPP-4 inhibitor use with BP was independent of the use of metformin and was stronger among male (OR, 4.46; 95% CI, 2.11-9.40) than female (OR, 1.88; 95%, CI 0.92-3.86) patients and strongest in patients younger than 70 years (OR, 5.59; 95% CI, 1.73-18.01). Patients with DPP-4 inhibitor-associated BP presented with higher mucosal involvement (22.2% vs 6.5%; P = .04) and lower mean (SD) peripheral eosinophil counts (399.8 [508.0] vs 1117.6 [1847.6] cells/μL; P = .01) than those with BP who had not been exposed to DPP-4 inhibitor. Discontinuation of DPP-4 inhibitor treatment was followed by improved clinical outcomes. CONCLUSIONS AND RELEVANCE: Vildagliptin and, to a lesser extent, linagliptin are associated with an increased risk of BP. This may partly explain the increasing incidence of BP in Israel. Discontinuation of DPP-4 inhibitor treatment in patients with diabetes should be considered when BP is diagnosed.
引用
- Kridin K, Bergman R. Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients. JAMA Dermatol. 2018. PMID: 30090931. doi:10.1001/jamadermatol.2018.2352
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。